Analytical Data
-
基因名
DRAP1
- Application
-
别名
Dr1-associated protein 1Negative cofactor 2-alpha ;NC2-alpha
-
种属
Human
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q14919
-
表达区间
4-198aa
-
分子量
48.2 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DRAP1 (DRAP1, also known as D1 protein) is a critical regulator of the cellular response to various stressors and is implicated in several essential biological processes, such as apoptosis and cell proliferation. Research into DRAP1 has gained momentum due to its potential role in the pathophysiology of various diseases, including cancers and neurodegenerative disorders. The protein interacts with several key signaling pathways, particularly those involving the tumor suppressor p53 and the apoptosis regulator Bcl-2, suggesting that it may play a pivotal role in maintaining cellular homeostasis under stress conditions. Recent studies have focused on the development and characterization of recombinant DRAP1 protein to better understand its structure-function relationships and biological activities. Recombinant protein production allows for the investigation of DRAP1’s conformational states, oligomerization, and interaction with other proteins, which is crucial for elucidating its functional mechanisms. Additionally, the use of recombinant DRAP1 in experimental settings is paving the way for potential therapeutic applications, as modulating its activity could yield novel strategies for cancer treatment and neuroprotection. Continued research on DRAP1 and its recombinant forms is necessary to establish its role as a biomarker for disease progression and to explore its therapeutic potential in the modulation of apoptotic pathways.
